- Home
- USEA vs ABVC Comparison
USEA vs ABVC Comparison
Compare USEA & ABVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USEA
- ABVC
- Stock Information
- Founded
- USEA 2004
- ABVC 2015
- Country
- USEA Greece
- ABVC United States
- Employees
- USEA N/A
- ABVC N/A
- Industry
- USEA Marine Transportation
- ABVC Biotechnology: Pharmaceutical Preparations
- Sector
- USEA Consumer Discretionary
- ABVC Health Care
- Exchange
- USEA Nasdaq
- ABVC Nasdaq
- Market Cap
- USEA 16.1M
- ABVC 12.8M
- IPO Year
- USEA N/A
- ABVC N/A
- Fundamental
- Price
- USEA $1.84
- ABVC $0.49
- Analyst Decision
- USEA Strong Buy
- ABVC
- Analyst Count
- USEA 1
- ABVC 0
- Target Price
- USEA $6.00
- ABVC N/A
- AVG Volume (30 Days)
- USEA 35.6K
- ABVC 107.7K
- Earning Date
- USEA 02-18-2025
- ABVC 03-12-2025
- Dividend Yield
- USEA 16.39%
- ABVC N/A
- EPS Growth
- USEA N/A
- ABVC N/A
- EPS
- USEA N/A
- ABVC N/A
- Revenue
- USEA $46,160,000.00
- ABVC $509,788.00
- Revenue This Year
- USEA $27.55
- ABVC N/A
- Revenue Next Year
- USEA $5.76
- ABVC N/A
- P/E Ratio
- USEA N/A
- ABVC N/A
- Revenue Growth
- USEA 11.18
- ABVC N/A
- 52 Week Low
- USEA $1.63
- ABVC $0.41
- 52 Week High
- USEA $3.00
- ABVC $1.73
- Technical
- Relative Strength Index (RSI)
- USEA 50.46
- ABVC 40.02
- Support Level
- USEA $1.77
- ABVC $0.46
- Resistance Level
- USEA $1.89
- ABVC $0.55
- Average True Range (ATR)
- USEA 0.06
- ABVC 0.03
- MACD
- USEA 0.01
- ABVC -0.00
- Stochastic Oscillator
- USEA 55.56
- ABVC 29.66
About USEA United Maritime Corporation
United Maritime Corp operates as a shipping company currently specializing in the seaborne transportation of dry bulk commodities. It currently operates one LR2 tanker vessel and three Capesize dry bulk vessels, two Kamsarmax dry bulk vessels, and three Panamax dry bulk vessels, with an aggregate cargo-carrying capacity of approximately 1,004,289 dwt.
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. For its drug products, it is focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm is specialized in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.